Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Bausch Health Companies Inc. (BHC) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Healthcare · Drug Manufacturers - Specialty & Generic
Laval, QC H7L 4A8, Canada
bauschhealth.com
Price
$6.21
Market Cap
$2.4B
Employees
20,300
Beta
0.38
Avg Volume
4,250,043
Last Dividend
$1.28
CEO
Mr. Thomas J. Appio
Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 11 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was Jul 29, 2026.
EPS surprise history — vs analyst consensus · 5 prints of vendor history
+4.2%
Feb '26
-12.7%
Feb '26
+13.0%
Apr '26
+6.2%
May '26
+24.8%
Jul '26
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Jul 29, 2026 | $1.01 | $1.26 +24.8% | — | — |
| May 20, 2026 | $2.91 | $3.09 +6.2% | — | — |
| Apr 29, 2026 | $0.69 | $0.78 +13.0% | — | — |
| Feb 18, 2026 | $1.26 | $1.10 -12.7% | — | — |
| Feb 10, 2026 | $0.96 | $1.00 +4.2% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Jul 30, 2026 | 10-Q | View |
| Jul 29, 2026 | 8-K | View |
| Jul 20, 2026 | 4 | View |
| Jul 17, 2026 | 4 | View |
| Jul 15, 2026 | 4 | View |
| Jul 2, 2026 | 4 | View |
| Jul 2, 2026 | 4 | View |
| Jul 2, 2026 | 4 | View |
| Jul 1, 2026 | 8-K | View |
| Jun 1, 2026 | SD | View |
| May 26, 2026 | 4 | View |
| May 26, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 11, 2026 10:42am (just now)
Current data · timestamped when a report runs
$6.21
Change · Aug 11
-0.14 (-2.28%)
Day Range
$6.18 – $6.30
52-Week Range
$4.33 – $8.69
50-Day MA
$5.14
200-Day MA
$5.85
Volume
12,590.00
Share Structure
Outstanding
373,901,440.00
Float
258,554,634.00
Free Float
69.2%
Normal free float
— 69.2% of shares trade freely, ~30.8% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
14.77
Stock Price: $6.21
EPS (Diluted): 0.42
EPS (Diluted): 0.42
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
6.17
Stock Price: $6.21
Total Equity: $377.00M
Shares: 375,000,000
Total Equity: $377.00M
Shares: 375,000,000
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
7.23
Market Cap: $2.37B
Total Debt: $20.82B
Cash: $1.31B
EBITDA: $3.02B
Total Debt: $20.82B
Cash: $1.31B
EBITDA: $3.02B
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$21.8B
Market Cap: $2.37B
Total Debt: $20.82B
Cash: $1.31B
Total Debt: $20.82B
Cash: $1.31B
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
—
Gross Profit: N/A
Revenue: $10.27B
Revenue: $10.27B
Missing from API: Gross Profit
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
17.7%
Operating Income: $1.81B
Revenue: $10.27B
Revenue: $10.27B
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
1.5%
Net Income: $157.00M
Revenue: $10.27B
Revenue: $10.27B
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
41.6%
Net Income: $157.00M
Total Equity: $377.00M
Total Equity: $377.00M
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
3.0%
Operating Income: $1.81B
Tax Rate: 67.3%
Equity: $377.00M
Total Debt: $20.82B
Cash: $1.31B
Tax Rate: 67.3%
Equity: $377.00M
Total Debt: $20.82B
Cash: $1.31B
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
1.47
Current Assets: $6.16B
Current Liabilities: $4.18B
Current Liabilities: $4.18B
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
55.22
Short-Term Debt: $225.00M
Long-Term Debt: $20.59B
Total Debt: $20.82B
Total Equity: $377.00M
Long-Term Debt: $20.59B
Total Debt: $20.82B
Total Equity: $377.00M
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
$27.38
Revenue: $10.27B
Shares: 375,000,000
Shares: 375,000,000
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$1.01
Total Equity: $377.00M
Shares: 375,000,000
Shares: 375,000,000
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$2.67
Operating CF: $1.40B
CapEx: -$397.00M
Shares: 375,000,000
CapEx: -$397.00M
Shares: 375,000,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
20.6%
Last Dividend: $1.28
Stock Price: $6.21
Stock Price: $6.21
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $157.00M
Net Income: $157.00M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Aug 6, 2026 1:46am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $8.4B | $8.1B | $8.8B | $9.6B | $10.3B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | — | — | — | — | — |
| Operating Income | $450.0M | $454.0M | $963.0M | $1.5B | $1.8B |
| Net Income | -$948.0M | -$225.0M | -$592.0M | -$46.0M | $157.0M |
| EBITDA | $2.0B | $1.8B | $2.2B | $2.8B | $3.0B |
| EPS | $-2.64 | $-0.62 | $-1.62 | $-0.13 | $0.42 |
| EPS (Diluted) | $-2.64 | $-0.62 | $-1.62 | $-0.13 | $0.42 |
Balance Sheet (Annual)
Last updated: Aug 6, 2026 1:46am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $582.0M | $564.0M | $947.0M | $1.2B | $1.3B |
| Total Current Assets | $5.6B | $4.2B | $5.6B | $5.8B | $6.2B |
| Total Assets | $29.2B | $25.7B | $27.4B | $26.5B | $26.4B |
| Current Liabilities | $5.2B | $3.9B | $4.3B | $6.8B | $4.2B |
| Long-Term Debt | $22.7B | $20.3B | $21.9B | $18.9B | $20.6B |
| Total Liabilities | $29.2B | $25.4B | $27.4B | $26.8B | $26.0B |
| Total Equity | -$34.0M | $260.0M | -$82.0M | -$322.0M | $377.0M |
| Retained Earnings | -$9.0B | -$9.2B | -$9.8B | -$9.8B | -$9.7B |
Cash Flow (Annual)
Last updated: Aug 6, 2026 1:46am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.4B | -$728.0M | $1.0B | $1.6B | $1.4B |
| Capital Expenditure | -$269.0M | -$218.0M | -$215.0M | -$337.0M | -$397.0M |
| Free Cash Flow | $1.2B | -$946.0M | $817.0M | $1.3B | $1.0B |
| Acquisitions (net) | $0 | -$45.0M | -$1.9B | — | — |
| Net Debt Issued / (Repaid) | -$1.3B | -$1.0B | $1.6B | -$799.0M | -$637.0M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $303.0M | -$1.5B | $371.0M | $239.0M | $124.0M |
Growth Trends (YoY %)
Last updated: Aug 6, 2026 1:46am (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -3.7% | +7.8% | +9.9% | +6.7% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | +0.9% | +112.1% | +60.5% | +17.3% |
| Net Income Growth | +76.3% | -163.1% | +92.2% | +441.3% |
| EBITDA Growth | -7.7% | +20.5% | +26.3% | +7.4% |
Dividend History (Last 20)
Last updated: Aug 6, 2026 1:46am (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2010-11-10 | $1.00 | — | — | — |
| 2010-08-30 | $0.10 | — | — | — |
| 2010-05-28 | $0.10 | — | — | — |
| 2010-03-04 | $0.09 | — | — | — |
| 2009-11-30 | $0.09 | — | — | — |
| 2009-08-28 | $0.09 | — | — | — |
| 2009-05-13 | $0.09 | — | — | — |
| 2009-03-06 | $0.38 | — | — | — |
| 2008-12-19 | $0.38 | — | — | — |
| 2008-08-21 | $0.38 | — | — | — |
| 2008-05-20 | $0.38 | — | — | — |
| 2008-03-25 | $0.38 | — | — | — |
| 2007-11-16 | $0.38 | — | — | — |
| 2007-08-16 | $0.38 | — | — | — |
| 2007-05-18 | $0.38 | — | — | — |
| 2007-03-22 | $0.38 | — | — | — |
| 2007-01-08 | $0.50 | — | — | — |
| 2006-11-20 | $0.13 | — | — | — |
| 2006-08-16 | $0.13 | — | — | — |
| 2006-05-19 | $0.13 | — | — | — |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Lenar Aimee J. | F-InKind | 5,260.00 | $4.83 | $25,406 |
| 2026-07-15 | Lenar Aimee J. | F-InKind | 23,395.00 | $4.89 | $114,402 |
| 2026-07-14 | LEE STEVEN HYOSIG | F-InKind | 3,125.00 | $4.75 | $14,844 |
Industry Benchmarks
Compares BHC against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for BHC — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for BHC — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for BHC — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for BHC — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · four lenses
No community reviews yet for BHC.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.525 · a5aac093 · 2026-08-10 20:52:14